InVivo Therapeutics’ CEO Scheduled to Appear on Business News Network’s “The Close” in Canada
"CAMBRIDGE, Mass. (April 26, 2013) - InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of neurotrauma conditions, today announced that CEO Frank Reynolds is scheduled to appear live in Toronto on Business News Network’s (BNN–TV) “The Close” on Monday, April 29th at approximately 4:50pm ET. BNN is Canada’s only all business and financial news channel. “The Close” is a weekday program anchored by Michael Hainsworth that airs from 3:30pm to 5:00pm ET and guides the viewer through the vital last half-hour of trading, zooms in on earnings reports and prepares the investor for the next trading day.
InVivo Therapeutics has pioneered a range of biodegradable devices utilizing biocompatible polymers that provide structural support to damaged nervous system tissue. Preventing tissue from scarring results in improved prognosis, and improved functional recovery after traumatic spinal cord injury (SCI).
Recently, the U.S. Food and Drug Administration (FDA) granted two approvals to InVivo, the first for Humanitarian Use Device (HUD) designation, which the Company believes will expedite the SCI product to market, and the second approval permits the Company to begin a first-in-man clinical trial....
Note to shorts: Big Media Exposure from Canada coming Monday, on a scale similar to CNBC for the USA.
More developments to follow as warrant reclassification figures will be reported 7 days later. Followup with PRs about ducks now all lined up for uplisting. IMO news by mid-May of enrollment of patients and hospital arrangements for date of study startup.
“We’ve leveraged our materials to create products for multiple neurotrauma conditions that exist outside of the spinal cord. As we conduct our human study, our team will finalize data for submission on multiple 510(k) products that are on track to hit the market by Q4 2014. The market opportunities for each 510(k) product exceed $1 Billion annually. In September 2013, we plan to submit an IND to the FDA to begin human studies with our promising injectable nerve pain treatment. The market for InVivo’s spinal pain treatment is a $23 Billion market opportunity and needs of baby boomers will maintain steady growth. We’re perfectly positioned to create a new clinical franchise in medicine using our biomaterials and we’ll continue to create shareholder value as we scale our company for rapid growth,” said Reynolds."
"Locking is when the MM on the ask moves to the bid in an attempt to back the bidding MM off to drive the price of the stock down. Thus by attacking the bid, both the bid and the ask are the same price. Sometimes a stock will stay locked for sometime if the bidding Market Maker does not move off the bid wanting more stock."